An inflammatory protein called ASC was found in laboratory models to help accelerate the toxic spread of alpha-synuclein through the brain in Parkinson’s disease, implying that this protein may be a useful disease target, a new study suggests. “Importantly, … the ASC protein presents as a promising target,” the…

Implanting electrodes into the brain triggers inflammation by activating a group of immune signaling proteins called the inflammasome — which detects infection and, in turn, prompts a strong inflammatory response, a new study shows. These findings may open new avenues to improve deep brain stimulation, a type of therapy used…

ZyVersa Therapeutics announced that a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support work into IC 100 as a potential antibody-based therapy for Parkinson’s disease. Robert Keane, PhD, and Juan Pablo de Rivero Vaccari, PhD, professors at the University of…

Hidrox, a compound extracted from olives, can significantly ease Parkinson’s motor symptoms, reduce alpha synuclein buildup, and slow neurodegeneration in animal models of the disease, a recent study has found. Though Hidrox is known mostly for its antioxidant effects, its benefits in Parkinson’s went beyond a decline…

An inflammatory pathway that plays a key role in the proper removal of faulty cells during brain development could open new avenues for studying or treating neurological diseases, including Parkinson’s. The study, “AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment,” was published in Nature. During…

Researchers in Australia are planning to test therapies already being used in other inflammatory conditions, as well as new compounds, for their potential to block brain inflammation and halt Parkinson’s disease progression. Conducted by researchers at The University of Queensland (UQ) in Australia, the study, “Pharmacological…